Synthroid (Levothyroxine) and Benzodiazepines: Drug Interaction Guide

Levothyroxine, sold under the brand name Synthroid, is a synthetic thyroid hormone (T4) prescribed for hypothyroidism. Benzodiazepines such as alprazolam, lorazepam, diazepam, and clonazepam are central nervous system depressants commonly used to manage anxiety, panic disorder, and sleep disturbances. This article examines the potential interaction between levothyroxine and benzodiazepines when used concurrently, rather than evaluating the clinical appropriateness of either medication for individual patients, which remains within the purview of the treating physician.

Levothyroxine and benzodiazepines do not share a cytochrome P450 or transporter-based drug interaction, so there is no established pharmacokinetic conflict between the classes. The clinically relevant issues are pharmacodynamic and absorption-related instead: undertreated hypothyroidism can make benzodiazepine sedation more pronounced, correcting hypothyroidism can unmask anxiety that a benzodiazepine is treating, and taking the two products at the exact same time may modestly reduce levothyroxine absorption. None of this is described in the FDA label as a formal drug interaction, and this combination should still be reviewed by a pharmacist or prescriber for the individual patient, particularly around timing and monitoring.

Why this combination comes up so often

Hypothyroidism and anxiety disorders share overlapping symptoms, including fatigue, irritability, poor concentration, and sleep disruption. Because of this overlap, it is common for a patient stabilized on levothyroxine to also be prescribed a benzodiazepine for anxiety or insomnia, or for a patient already on a benzodiazepine to be diagnosed with hypothyroidism later. Published studies have reported that anxiety symptoms are more common in people with hypothyroidism than in the general population, but the exact prevalence figures vary by study population and screening tool, and a specific percentage should not be treated as fixed without checking the primary study behind it.

Do these drugs compete for the same metabolic pathways?

No, and this is the most reassuring part of the pharmacology.

Levothyroxine. Levothyroxine is a prohormone converted to active triiodothyronine (T3) mainly by deiodinase enzymes in the liver, kidney, and peripheral tissue, not by cytochrome P450 enzymes. The FDA-approved prescribing information for Synthroid does not list benzodiazepines among the drug classes known to interact with levothyroxine metabolism or absorption in a clinically significant way. Levothyroxine is highly protein-bound (over 99%, mainly to thyroxine-binding globulin), and clinically meaningful protein-binding displacement is associated with a small number of drugs such as phenytoin and salicylates, not benzodiazepines.

Benzodiazepines. Most benzodiazepines are metabolized hepatically. Alprazolam, diazepam, and clonazepam depend substantially on CYP3A4 (diazepam also involves CYP2C19). Lorazepam, oxazepam, and temazepam are metabolized by direct glucuronidation and bypass CYP enzymes almost entirely, which is why they are often favored in patients with hepatic impairment or complex medication regimens.

Because levothyroxine is not a meaningful CYP3A4, CYP2C19, or UGT substrate, inhibitor, or inducer, it should not be expected to alter benzodiazepine clearance, and benzodiazepines are not expected to alter deiodinase activity or thyroid hormone protein binding. Standard interaction references (Lexicomp, Micromedex) classify levothyroxine and benzodiazepines as having no established pharmacokinetic interaction. That classification reflects an absence of demonstrated conflict rather than a large body of dedicated interaction trials, and a reader relying on this for a specific clinical decision should confirm current guidance with a pharmacist, since interaction database content changes.

The absorption question: does timing matter?

The one absorption-related concern that plausibly applies is general, not benzodiazepine-specific. Levothyroxine requires an acidic gastric environment for reliable dissolution, and its absorption is well documented to be reduced by calcium and iron supplements, antacids, proton pump inhibitors, sucralfate, and cholestyramine. Some benzodiazepine tablet formulations contain calcium-based or other mineral excipients as fillers, so taking a benzodiazepine at the exact same time as levothyroxine could theoretically blunt levothyroxine absorption slightly, though this is an extrapolation from known excipient interactions rather than a benzodiazepine-specific finding confirmed in a dedicated trial.

The standard, well-established practice recommended for levothyroxine generally, regardless of what else a patient takes, is to take it on an empty stomach 30 to 60 minutes before food or other medications, and to keep dosing timing consistent day to day. A practical approach for co-prescribed patients is to separate a daytime benzodiazepine dose from the morning levothyroxine dose by at least a few hours; a bedtime benzodiazepine dose used for insomnia is naturally separated by many hours and is not a timing concern.

The pharmacodynamic overlap: where the real nuance is

Untreated or undertreated hypothyroidism can amplify CNS depression. Hypothyroidism slows cerebral metabolism, and clinical experience and pathophysiology both support that under-replaced patients can be more sensitive to sedating drugs, including benzodiazepines, opioids, and anesthetics. This is a plausible and clinically accepted mechanism, though exact quantitative estimates of how much cerebral blood flow or metabolism changes in a given patient are not something this article can state precisely without checking the specific imaging study being cited elsewhere online, and such numbers should be treated cautiously.

Correcting hypothyroidism can unmask or increase anxiety symptoms. As levothyroxine restores euthyroidism, some patients report feeling more activated, with a higher heart rate and more perceived anxiety. This is not a drug-drug interaction; it is the expected physiological effect of normalizing thyroid hormone levels, and it can mean a benzodiazepine dose that felt adequate during hypothyroidism becomes insufficient once TSH normalizes. It can also mean that if the levothyroxine dose is too high (TSH suppressed), the resulting mild thyrotoxicosis is itself producing anxiety, tremor, and palpitations that should be treated by lowering the levothyroxine dose, not by increasing the benzodiazepine.

Evidence-status assessment: what is known, plausible, or unverified

A practical decision framework based on TSH

• TSH elevated (undertreated hypothyroidism): Optimize the levothyroxine dose first. Some anxiety and sedation-sensitivity issues may improve as thyroid function normalizes. Avoid escalating the benzodiazepine dose until TSH has been in range for several weeks.
• TSH within the normal range: Anxiety symptoms at this point are less likely to be thyroid-driven. Consider evaluation for a primary anxiety or panic disorder, and consider whether an SSRI, SNRI, or psychotherapy might reduce reliance on a benzodiazepine.
• TSH suppressed (over-replacement): Excess thyroid hormone itself can cause anxiety, tremor, palpitations, and insomnia. The appropriate response is to lower the levothyroxine dose, not to increase the benzodiazepine dose.

Monitoring for patients on both medications

A reasonable monitoring approach, consistent with standard thyroid monitoring practice, includes:

Baseline: TSH and free T4, a review of all medications and supplements that affect levothyroxine absorption (calcium, iron, proton pump inhibitors, antacids), and documentation of baseline anxiety severity.

Around 6 to 8 weeks after starting or changing either medication: Recheck TSH and free T4. If TSH has moved meaningfully from baseline, review adherence and dose timing before assuming a drug interaction is responsible, since inconsistent levothyroxine timing is a far more common cause of TSH variability than benzodiazepine co-administration.

Ongoing, roughly every 6 to 12 months, or per the prescriber's standard interval: Routine TSH monitoring, and periodic reassessment of whether the benzodiazepine is still needed, since guidance from accountable bodies on benzodiazepine prescribing generally recommends reevaluating continued use rather than renewing indefinitely.

Special populations

Older adults. Widely used geriatric prescribing criteria identify benzodiazepines as potentially inappropriate in adults over 65 because of fall risk, cognitive impairment, and delirium risk. Hypothyroidism also becomes more common with age, particularly in women. When both conditions are present, a glucuronidated benzodiazepine such as lorazepam or oxazepam, at the lowest effective dose, is often preferred over a long-half-life or CYP3A4-dependent agent, but this choice should be made by the prescriber based on the full medical picture.

Pregnancy. Levothyroxine dosing requirements typically increase during pregnancy and are managed by TSH monitoring under obstetric or endocrine guidance. Benzodiazepines carry known risks of fetal and neonatal effects and are generally avoided in pregnancy unless the benefit clearly outweighs the risk; this is a decision for the prescriber and should not be inferred from this article.

Obstructive sleep apnea. Both untreated hypothyroidism and benzodiazepines can worsen sleep-disordered breathing. In a patient with known or suspected OSA, adding a benzodiazepine while hypothyroidism remains undertreated raises the combined risk of nocturnal hypoxia, and this scenario warrants closer clinical attention rather than routine co-prescribing.

Which benzodiazepines are more commonly preferred with levothyroxine

No benzodiazepine is contraindicated with levothyroxine. Practical differences relate to metabolism and half-life rather than a levothyroxine-specific conflict.

• Lorazepam and oxazepam: Metabolized by direct glucuronidation, no CYP involvement, no active metabolites. Often preferred in patients with hepatic impairment or complex medication lists.
• Alprazolam: CYP3A4-dependent, so it can interact with other CYP3A4 inhibitors or inducers (such as certain antifungals or macrolide antibiotics) independent of levothyroxine.
• Diazepam and clonazepam: Long half-lives with active metabolites, CYP3A4 or CYP2C19 dependent, with accumulation risk in older adults or those with hepatic impairment.

Patient counseling points

• Take levothyroxine consistently, at the same time each day, on an empty stomach, and separate it from calcium, iron, and, as a precaution, from benzodiazepine doses by a few hours.
• Inconsistent levothyroxine timing is a more common explanation for unexpected TSH changes than an interaction with a benzodiazepine.
• Do not stop either medication abruptly. Stopping a benzodiazepine suddenly after regular use can cause withdrawal, including seizure risk in some patients. Stopping levothyroxine leads to a gradual return of hypothyroid symptoms over one to a few weeks.
• Alcohol increases benzodiazepine sedation and can also interfere with a consistent morning medication routine.
• New confusion, excessive sleepiness, or falls should prompt urgent medical evaluation rather than waiting for a routine follow-up, since these can reflect either over-replacement of thyroid hormone or benzodiazepine accumulation.

What is established, what is plausible, and what is not established

Established: Levothyroxine is not metabolized through cytochrome P450 pathways, and there is no documented pharmacokinetic interaction between levothyroxine and benzodiazepines in major interaction databases or the FDA label. Levothyroxine absorption is well documented to be reduced by calcium, iron, and certain other substances taken at the same time.

Plausible but not rigorously quantified for this specific pairing: That undertreated hypothyroidism meaningfully increases sensitivity to benzodiazepine sedation, that correcting hypothyroidism can unmask anxiety symptoms, and that benzodiazepine tablet excipients could modestly reduce levothyroxine absorption if taken simultaneously.

Not established: Any precise numeric estimate (a specific percentage reduction in absorption, a specific prevalence of anxiety in hypothyroid patients, a specific magnitude of cerebral blood flow change) attributed to this drug pairing specifically. Readers should treat such numbers, wherever encountered, as needing verification against the original study rather than as settled facts.

This article does not provide individualized dosing or timing instructions. Dose adjustments for either levothyroxine or a benzodiazepine should be made by the prescribing clinician based on TSH trends, symptom review, and the patient's full medication list.

References

Earlier versions of this article contained specific data points regarding the incidence of anxiety in hypothyroid patients, quantified changes in drug absorption, and particular neuroimaging results related to cerebral perfusion in hypothyroidism. These claims could not be substantiated through primary literature review and have either been generalized or excluded from the current version. Before restoring any numerical data to this article, a subject matter expert should retrieve and validate the original research.